Bio-Techne Corp $TECH Shares Acquired by Royce & Associates LP

Posted by Brenda Bartman on May 26th, 2026

Royce & Associates LP lifted its stake in shares of Bio-Techne Corp (NASDAQ:TECH – Free Report) by 2.8% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 678,502 shares of the biotechnology company’s stock after purchasing an additional 18,468 shares during the period. Royce & Associates LP’s holdings in Bio-Techne were worth $39,903,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Asset Management One Co. Ltd. grew its position in shares of Bio-Techne by 2.7% during the fourth quarter. Asset Management One Co. Ltd. now owns 5,752 shares of the biotechnology company’s stock worth $341,000 after buying an additional 153 shares in the last quarter. Accredited Investors Inc. grew its position in shares of Bio-Techne by 2.7% during the fourth quarter. Accredited Investors Inc. now owns 6,052 shares of the biotechnology company’s stock worth $356,000 after buying an additional 161 shares in the last quarter. Allworth Financial LP grew its position in shares of Bio-Techne by 28.4% during the third quarter. Allworth Financial LP now owns 786 shares of the biotechnology company’s stock worth $44,000 after buying an additional 174 shares in the last quarter. Oppenheimer & Co. Inc. grew its position in shares of Bio-Techne by 3.5% during the fourth quarter. Oppenheimer & Co. Inc. now owns 5,351 shares of the biotechnology company’s stock worth $315,000 after buying an additional 181 shares in the last quarter. Finally, Angeles Wealth Management LLC grew its position in shares of Bio-Techne by 3.4% during the third quarter. Angeles Wealth Management LLC now owns 5,703 shares of the biotechnology company’s stock worth $317,000 after buying an additional 189 shares in the last quarter. 98.95% of the stock is owned by institutional investors and hedge funds.

Bio-Techne Stock Performance

Shares of TECH opened at $48.21 on Tuesday. The stock has a 50 day moving average price of $52.14 and a 200 day moving average price of $58.12. The company has a quick ratio of 3.18, a current ratio of 4.49 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $7.55 billion, a price-to-earnings ratio of 69.87, a price-to-earnings-growth ratio of 3.75 and a beta of 1.41. Bio-Techne Corp has a 52-week low of $43.19 and a 52-week high of $72.16.

Bio-Techne (NASDAQ:TECH – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.02). Bio-Techne had a net margin of 9.05% and a return on equity of 13.57%. The business had revenue of $311.42 million during the quarter, compared to analyst estimates of $316.11 million. During the same period last year, the company earned $0.56 earnings per share. The business’s revenue for the quarter was down 1.5% compared to the same quarter last year. Research analysts predict that Bio-Techne Corp will post 1.69 EPS for the current fiscal year.

Bio-Techne Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Shareholders of record on Monday, May 18th will be paid a $0.08 dividend. The ex-dividend date is Monday, May 18th. This represents a $0.32 dividend on an annualized basis and a yield of 0.7%. Bio-Techne’s payout ratio is currently 46.38%.

Analysts Set New Price Targets

TECH has been the subject of a number of research analyst reports. Citigroup lowered their price target on Bio-Techne from $80.00 to $70.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Evercore set a $50.00 price target on Bio-Techne in a report on Thursday, May 7th. Benchmark reaffirmed a “buy” rating on shares of Bio-Techne in a report on Tuesday, February 3rd. TD Cowen reaffirmed a “buy” rating on shares of Bio-Techne in a report on Tuesday, March 17th. Finally, Royal Bank Of Canada set a $62.00 price target on Bio-Techne and gave the company an “outperform” rating in a report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Bio-Techne currently has a consensus rating of “Moderate Buy” and an average price target of $65.92.

Check Out Our Latest Report on Bio-Techne

Bio-Techne Company Profile

(Free Report)

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.